Macular Degeneration to dominate the Retinal Disorder Treatment Market through 2028
Global Retinal Disorder Treatment Market
to be driven by the increasing prevalence of retinal disorders during the
forecast period.
According to TechSci Research report, “Retinal
Disorder Treatment Market - Global Industry Size, Share, Trends, Opportunity,
and Forecast, 2018-2028F”, Global
Retinal Disorder Treatment Market is anticipated to grow at an impressive rate
in the forecast period, 2024-2028. Global Retinal Disorder Treatment
market is driven by factors such as the rising prevalence of retinal diseases,
the growing aging population, increasing awareness about ocular health and
early disease diagnosis and treatments. Additionally, use of gene therapies and
cell therapies for the treatment of retinal disorders is expected to create
lucrative opportunities for the growth of global retinal disorder treatment
market. Gene therapy is a promising new treatment option for retinal disorders
caused by genetic mutations. In this approach, a functional copy of the
defective gene is introduced into the patient's cells to correct the mutation. Stem
cell therapy is another promising approach to treating retinal disorders. Stem
cells can be used to replace damaged retinal cells or to stimulate the growth
of new retinal tissue. Researchers have successfully used stem cells to treat
retinal degeneration in animal models, and clinical trials are underway to test
the safety and efficacy of this approach in humans.
Also, another advancement that will spur
the growth of global retinal disorder treatment market is artificial retina. An
artificial retina, also known as a retinal implant, is a device that can
restore vision in patients with severe retinal damage. The implant consists of
a small chip that is surgically implanted into the eye, and an external device
that sends visual information to the chip. The chip then stimulates the
remaining retinal cells to create a visual image. Several retinal implants have
been developed and are currently available for clinical use.
However, challenges such as accurate
diagnosis and access to treatment and care are some of the major factors
restraining the growth of global retinal disorder treatment market. Many
retinal disorders have similar symptoms, making it difficult to differentiate
between them. In addition, some retinal disorders may not cause symptoms until
they have progressed to an advanced stage. Early diagnosis is crucial in
preventing vision loss, so there is a need for more accurate and efficient
diagnostic tools. Another challenge in treating retinal disorders is access to
treatment. Some treatments are expensive and may not be covered by insurance,
making them inaccessible to many patients. In addition, some treatments require
specialized equipment and expertise, which may not be available in all areas.
This can result in long wait times and delayed treatment.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Retinal Disorder Treatment Market.”
Global Retinal Disorder Treatment Market can be segmented type, by dosage form,
by distribution channel, and by region. Based on type, Global Retinal Disorder
Treatment market can be categorized into macular degeneration, diabetic
retinopathy, and others. The macular degeneration segment dominated the market
in 2022 and will continue maintaining its dominance through 2028. Age-related
macular degeneration (AMD) is one of the most common retinal disorders,
affecting millions of people worldwide. AMD is a progressive condition that
causes damage to the macula, the small central part of the retina responsible
for detailed vision. While there is no cure for AMD, several treatments are
available that can slow the progression of the disease and improve vision. One
of the most promising treatments for AMD is anti-VEGF therapy. VEGF, or
vascular endothelial growth factor, is a protein that stimulates the growth of
new blood vessels in the retina. In AMD, the abnormal growth of blood vessels
can lead to fluid leakage and scarring, causing vision loss. Anti-VEGF therapy
involves the injection of a medication that blocks the activity of VEGF,
preventing the growth of new blood vessels and reducing inflammation in the
retina. Other treatments for AMD include laser therapy, which involves the use
of a laser to destroy abnormal blood vessels in the retina, and photodynamic
therapy, which involves the injection of a medication that is activated by a
laser to destroy abnormal blood vessels. Additionally, lifestyle changes such
as quitting smoking, maintaining a healthy diet, and exercising regularly can
help slow the progression of AMD.
However,
diabetic retinopathy segment is expected to register the highest growth during
the forecast period owing to the increasing prevalence of diabetes among the
population.
In terms of
distribution channel, the global retinal disorder treatment market can be
classified into hospital pharmacy, online pharmacy, and retail pharmacy. The
hospital pharmacy segment dominated the market in 2022 and will continue
maintaining its dominance through 2028. This can be ascribed to the growing use
of drugs that require an injectable form of administration, which makes access
to a hospital pharmacy easier. However, increasing internet penetration,
growing smartphone and internet users worldwide will support the growth of
global retinal disorder treatment market.
Major companies operating in the Global Retinal
Disorder Treatment Market are:
- Santen Pharmaceutical Co. Ltd.
- Regeneron Pharmaceuticals Inc.
- Graybug Vision, Inc.
- Shire (Takeda Pharmaceutical Company
Limited)
- Bayer AG
- Genentech, Inc.
- Acucela Inc.
- Pfizer, Inc.
- Kubota Pharmaceutical Holdings Co., Ltd.
- Allergan plc. (AbbVie Inc.),
Download Free Sample Report
Customers can also request for 10% free
customization on this report.
“Asia Pacific region is expected to register the highest growth in the global
retinal disorder treatment market on account of the growing population in the
region which is susceptible to various kinds of retinal disorders especially in
China and India. Additionally, aging population in the region in countries like
Japan, India, and China which is susceptible to diseases like diabetic
retinopathy, age related macular degeneration, among others.” said Mr. Karan
Chechi, Research Director with TechSci Research, a research based global
management consulting firm.
Retinal Disorder Treatment Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented
By Type (Macular Degeneration, Diabetic Retinopathy, Others), By Dosage Form
(Gels, Eye Solution, Capsules & Tablets, Eye Drops, Others), By
Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), By
Region and Competition”, has evaluated
the future growth potential of Global Retinal Disorder Treatment Market and
provides statistics & information on market size, structure, and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Retinal Disorder Treatment Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com